NCT06092242View on ClinicalTrials.gov

The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 15, 2023

Primary Completion Date

October 15, 2025

Study Completion Date

October 15, 2027

Conditions
Colorectal Cancer
Interventions
DRUG

Tas-102(Suyuan) combined with bevacizumab

Tas-102: po 35 mg/m2, bid, d1-5, d8-12, Q4 wks; bevacizumab: intravenous drip 5 mg/kg, D1, D15, Q4 wks.

Trial Locations (1)

271000

The Second Affiliated Hospital of Shandong First Medical University, Tai’an

All Listed Sponsors
lead

The Second Affiliated Hospital of Shandong First Medical University

OTHER

NCT06092242 - The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter